Results 131 to 140 of about 4,732,777 (361)

Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer.

Cancer Cell, 2022
Adele M. Nicolas, M. Pesic, Esther Engel, Paul K Ziegler, M. Diefenhardt, Kilian B. Kennel, F. Buettner, Claire Conche, V. Petrocelli, Eiman Elwakeel, A. Weigert, A. Zinoveva, Maximilian Fleischmann, B. Häupl, Cem Karakütük, H. Bohnenberger, M. H. Mosa, L. Kaderali, J. Gaedcke, M. Ghadimi, F. Rödel, M. C. Arkan, T. Oellerich, C. Rödel, E. Fokas, F. Greten   +25 more
semanticscholar   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, EarlyView.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis [PDF]

, 2012
Polina Khrizman, Joyce C. Niland, Anna ter Veer, Dana Milne, Kelli Bullard Dunn, William E. Carson, Paul F. Engstrom, Stephen Shibata, John M. Skibber, Martin R. Weiser, Deborah Schrag, Al B. Benson   +11 more
openalex   +1 more source

Engineered Bacteria‐Vesicle Delivered Lactate Reprogramming Boosts Tumor Radiosensitivity

Advanced Science, EarlyView.
We engineered a bacterial‐vesicular dual‐delivery platform that targets LOx to colorectal tumors, enabling lactate clearance, immune microenvironment remodeling, and microbiota modulation. This microbe–metabolism synergistic strategy effectively sensitizes colorectal cancer to radiotherapy, offering a promising approach to overcome radioresistance ...
Fei Peng, Zhe Lei, Zhehao Zhang, Zhiyue Su, Chonghai Zhang, Huan Yang, Shu Liu, Mengyuan Hu, Yuhong Wang, Lingchuan Guo, Lin Hu, Kai Yang   +11 more
wiley   +1 more source

Does loss of ARID1A expression affect neoadjuvant chemoradiotherapy response in rectal carcinomas?

Polish Journal of Pathology
This study evaluated the difference of ARID1A protein immunoexpression between responders and non-responders to neoadjuvant chemoradiotherapy in locally advanced rectal cancers.
Nagehan O. Barisik, Sibel Sensu, Sevinc H. Keser, Yesim S. Gurbuz, Ozgul Ozdemir, Ramazan O. Yuceer, AylinE. Gul, Nusret Erdogan   +7 more
doaj   +1 more source

A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?

Case Reports in Pathology, 2015
Background. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported.
Sebahattin Celik, Remzi Erten, Abdulsamed Batur, Burak Suvak   +3 more
doaj   +1 more source

Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single‐Center Retrospective Study

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) with arterial abutment is a complex, high‐risk surgery. We aimed to investigate the clinicopathological features, risk factors, and learning curve for local recurrence after pancreatectomy for PDAC with arterial abutment.
Jun Ishida, Hirochika Toyama, Takayuki Kodama, Yoshihide Nanno, Takuya Mizumoto, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Tomoo Ito, Takumi Fukumoto   +9 more
wiley   +1 more source

Metabolomics Assisted by Transcriptomics Analysis to Reveal Metabolic Characteristics and Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy with TCbHP Regime in HER2 Breast Cancer

, 2023
Ningning Zhang, Yuxin Huang, Guanwen Wang, Zhouhong Jing, Junjie Zeng, Yu Feng, Xianjun Pan, Wenqi Zhou, Xiaohua Zeng   +8 more
openalex   +1 more source

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review

Annals of Gastroenterological Surgery, EarlyView.
We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source